• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Valeant bid for Allergan heats up, Pershing plans to replace Allergan board members

Article

Allergan says it will “carefully review and consider” a revised proposal from Valeant of $53.8 billion bid-while Pershing Square, the hedge fund that owns 9.7 percent of Allergan is calling to replace the company’s board.

Irvine, CA-Allergan says it will “carefully review and consider” a revised proposal from Valeant of $53.8 billion bid-while Pershing Square, the hedge fund that owns 9.7 percent of Allergan is calling to replace the company’s board. 

Valeant recently increased its offer to $72 in cash and 0.83 shares of Valeant stock, after Allergan swiftly rejected its initial offer of $48.30 in cash and 0.83 shares of Valeant stock.

“We believe our revised offer provides enormous value to both Valeant and Allergan shareholders,” says Valeant CEO and Chairman J. Michael Pearson. “We strongly believe that applying Valeant's operating philosophy, strategy, and financial discipline to a broader set of durable assets will continue to create substantial returns for shareholders over the short, intermediate, and long term. We are very committed to getting this deal done, and are now modifying our offer with the assistance of Pershing Square to increase the economics for all Allergan shareholders.” 

During a conference call with Pearson, Pershing Square CEO Bill Ackman told investors he has requested a special meeting, during which Pershing plans to replace a majority of the company’s directors, according to Reuters. The meeting is planned for as early as August 7, but Allergan could delay the meeting to as late as November.

The New York Times, which calls the deal “one of the most confounding takeover attempts in recent memory,” said the move to replace Allergan’s board members would increase the pressure on Allergan’s management. 

Related Videos
Megan Cavet, PhD
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Shelley Cutler, OD, FAAO, outlines her key takeaways from this year's IKA symposium
© 2024 MJH Life Sciences

All rights reserved.